INTRODUCTION
With the ultimate goal of developing methods to treat human disease, small animal models are used extensively in cardiovascular, orthopedic, and cancer research. [1] [2] [3] The advantages of using small animals include short gestation times, low maintenance costs and ease of genetic manipulation. 4 In order to study disease at scales suitable for small animals, high-resolution imaging techniques (i.e., micro-imaging) have been developed; these include micro magnetic resonance imaging, 5, 6 micro positron emission tomography, 7 micro-ultrasound, 8, 9 and micro computed tomography (micro-CT). 10 Among these, micro-CT has been the most utilized, based on scientific publications in the last five years.
Micro-CT's ubiquity is attributable to the fact that the modality is quantitative, threedimensional, non-destructive, fast and cost-effective. Contrast in micro-CT is derived from the differential attenuation of x-rays by various tissues. Unfortunately, soft tissues, which have similar densities, have little differential CT contrast and exogenous agents are required to provide contrast.
For example, to image the vasculature, x-ray attenuating contrast agents are injected intravenously to "opacify" the vessels during the acquisition of the micro-CT scan. With these contrast agents, vascular imaging by micro-CT can potentially be utilized to reliably track the development of blood vessels during the process of angiogenesis and in studying the effect of novel therapies for re-vascularization. 11 For human imaging, CT contrast agents are typically small iodinated molecules, which are cleared within a few minutes through the renal system. However, micro-CT scan times can be as long as tens of minutes and successful imaging of the vasculature requires the use of contrast agents that clear from the blood over extended time periods. These agents are referred to as "blood pool" contrast agents.
Several CT blood pool contrast agents are available commercially for in vivo small animal research. 12, 13 These have been made possible by advances in nanotechnology and consist of particles large enough to evade immediate renal clearance (i.e. > 10 nm). 14 Initially, commercially available nanoparticle-based blood-pool contrast agents were iodine-based to take advantage of the strong attenuation of iodine at low energies (k-edge = 33.2 kEv) and included Fenestra VC (containing 50 mg/mL of iodine) and eXia 160 XL (containing 160 mg/mL of iodine). 13, 15 More recently gold-based agents have been developed (e.g. AuroVist 15 nm, containing 200 mg/mL of gold), which take advantage of the high density of gold. 16 These agents have been developed with the intent to deliver a high loading of metal (x-ray attenuator) in a small volume of contrast agent and thereby to provide higher contrast between the vessels and surrounding tissue.
Another class of metals appropriate for CT contrast agents is the lanthanides. These elements are of particular interest because they have k-edges near the average energies used in micro-CT (between 80 kVp and 120 kVp). This property makes the lanthanides ideally suited to use with specialized micro-CT techniques that take advantage of the spectral properties of materials, such as dual-energy imaging and spectral CT. Of the lanthanides, gadolinium has been used most extensively as a contrast agent for magnetic resonance imaging (MRI). Polymer particles decorated with gadolinium, such as the chelated derivative of diethylenetriaminepentaacetic acid and Gd(III) on a cross linked polymer nanogel, have been synthesized and used for vessel imaging of mice, but have Gd loading that is too low for CT imaging (typically < 0.5 mg/mL). [17] [18] [19] Lanthanide-based nanoparticles have also been explored for imaging, largely due to their abilities to alter proton relaxation times in MRI in the case of gadolinium 20, 21 or their photon upconversion capabilities in the case of NaLnF 4 (where Ln is a lanthanide and the system is codoped). [22] [23] [24] However, such particles are usually synthesized with hydrophobic ligands, 25 making it challenging to disperse them with high stability in blood. Chatterjee et al. achieved this by coating lanthanide-based nanoparticles with polyethyleneimine, reaching concentrations of 4.4 mg/mL (used subcutaneously for upconversion luminescence imaging). 22 Budijono et al. explored the encapsulation of lanthanide-based nanoparticles in block copolymer assemblies, and demonstrated the stability of these assemblies in serum media at low concentrations (< 1 mg/mL). 24 Similary, Zhu et al. used pH-responsive block copolymers to encapsulate gadolinium-based nanoparticles, and demonstrated that they could stabilize the nanoparticles in aqueous solution at low concentrations (< 0.1 mg/mL). 21 However, to date only Liu et al., have synthesized a lanthanide contrast agent with a concentration high enough for micro-CT imaging. 26 They encapsulated 70 mg/mL of ytterbium in 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-terminated poly(ethylene glycol) (PEG) and demonstrated circulation in the blood pool for approximately 20 minutes. However, even higher lanthanide concentrations and blood circulation times are required for high resolution imaging of the vasculature.
In this study, we present a simple and systematic method to prepare a lanthanide-based contrast agent for micro-CT applications, which require high contrast-element loading (> 100 mg/mL preferred) and long circulation times (ideally > 30 minutes). The high lanthanide concentration poses a significant challenge, particularly when paired with the need to add polymers, which are required to achieve long circulation times. Erbium, which we have demonstrated to be an excellent contrast agent for ex vivo imaging, was selected as the lanthanide. 27 Oleate-coated NaErF 4 nanoparticles (ErNP) were synthesized and encapsulated into core-shell nanoassemblies via nanoprecipitation using a series of amphiphilic block copolymers ( Figure 1 ). A sequence of optimization steps was then performed to identify an ideal polymer, which encapsulates a high lanthanide content while remaining colloidally stable after redispersion in saline and a mouseblood mimic. Once the ideal polymer was identified, the lanthanide-based contrast agent was evaluated in vivo over a period of one hour. To our knowledge, this is the first demonstration of the successful synthesis of an in vivo lanthanide-based blood pool agent that can be dispsersed into colloidally stable assemblies containing 100 mg/mL of erbium. 
EXPERIMENTAL SECTION

Materials and General Methods
Reagents were purchased from commercial suppliers as described in the Supporting Information (SI) and were used without further purification unless otherwise noted. Methods used in the synthesis and characterization of the materials are also presented in the SI document.
Nanoprecipitation for self-assembly of polymeric nanoparticles containing erbium nanoparticles
Erbium nanoparticles (ErNP) were synthesized by a previously reported method. 28, 29 The ErNP were self-assembled with purchased poly(ethylene glycol) (PEG)-poly(propylene glycol) (PPG) triblock copolymers (PEG 76 -PPG 22 -PEG 76 and PEG 137 -PPG 34 -PEG 137 where the subscripts indicate the degree of polymerization of the blocks), or synthesized diblock copolymers of PEG-poly(ecaprolactone)(PCL) (PEG 45 -PCL 20 , PEG 45 -PCL 51 , PEG 114 -PCL 51 , PEG 114 -PCL 97 ) or PEG-poly(llactide) (PEG 45 -PLA 25 , PEG 45 -PLA 52 , PEG 114 -PLA 53 , PEG 114 -PLA 122 ). 30, 31 ErNP (2 mg) were dissolved in 0.1 mL of tetrahydrofuran (THF). Separately, 8 mg of copolymer was dissolved in 0.1 mL of THF. These solutions were then combined and added dropwise to 1.8 mL of deionized water under magnetic stirring. After 1 hour, stirring was stopped and the solution was left uncapped for 12 hours to allow for organic solvent evaporation. The solutions were then dialyzed against 100 mL of deionized water for 2 days with 5 solvent changes. A 450 nm syringe filter was used to remove large aggregates and the samples were characterized by dynamic light scattering (DLS), transmission electron microscopy (TEM) and inductively coupled plasma mass spectrometry (ICP-MS).
Colloidal stability of the polymeric nanoparticles
The sterile polymeric nanoparticles containing ErNP were lyophilized prior to redispersion in saline. Saline is used as the solvent of the NPs prior to intravenous injection in vivo because it is isotonic with blood. Therefore the particles must remain colloidally stable in that environment.
DLS size measurements were performed on the redispersed ErNP and the average sizes of the samples were observed for up to one hour.
Varying the polymer content of the nanoparticles
The polymeric nanoparticles containing ErNP that remained colloidally stable after freezedrying and redispersion in saline, and that encapsulated relatively higher erbium amounts were selected (PEG 114 -PLA 53 ). Solutions with varying mass ratios were prepared. Synthesized ErNP (80 mg dissolved in 4 mL of THF) were added to 320, 160, 80 or 40 mg of PEG 114 -PLA 53 in 4 mL of THF. These solutions were combined and added dropwise to 100 mL of deionized water under magnetic stirring. After 1 hour, stirring was stopped and the suspension was left uncapped for 12 hours to allow for organic solvent evaporation. The suspensions were then dialyzed against 500 mL of deionized water for 2 days with 5 solvent changes. A 450 nm syringe filter was used to remove large aggregates and the samples were characterized by DLS, TEM and ICP-MS. The samples were lyophilized, sterilized and re-dispersed in 400 µL of saline. 10 µL of the samples were added to 990 µL of saline or mouse serum mimic for an hour-long time-course DLS study.
The mouse serum mimic was pH 7.4 phosphate buffered saline containing 0.5 µg/mL mouse immunoglobulins, 1 wt% bovine serum albumin and 0.1 wt% sodium azide. Colloidal stability in a mouse serum mimic in vitro will serve as an indicator of its stability in vivo. An increase in the average size signifies aggregation, which would lead to immune system detection followed by clearance from the blood pool in vivo.
General micro-CT imaging and analysis methods
Micro-CT images were acquired using the GE Locus Ultra (London, ON) with a protocol previously used to evaluate contrast agent distribution in vivo. 15 
Micro-CT imaging of erbium-containing polymeric nanoparticles
The relationship between CT contrast and erbium concentration was first determined by micro-CT. Erbium chloride was diluted in saline at erbium concentrations of 5, 10, 20 and 100 mg/mL, which acted as calibration standards. The linear regression between CT contrast (in HU) and erbium concentration was then used to measure the erbium concentrations resulting when 40 mg of each of the lyophilized 1:1 and 0.5:1 PEG 114 -PLA 53 :ErNP formulations were separately dispersed in 0.2 mL of saline.
Toxicity of the contrast agent
The 1:1 and 0.5:1 PEG 114 -PLA 53 :ErNP mass ratio formulations were tested. Details of these experiments are described in the SI document. Briefly, an in vitro cell viability assay was done using C2C12 mouse myoblast cells from Millipore Sigma (Oakville, ON). The cells were incubated with the contrast agent for 24 hours, after which cell viability was measured using a 3-
Following in vitro tests, the in vivo toxicity of the contrast agent was evaluated using the dorsal interscapular subcutaneous tissue of C57BL/6 male mice (25-30 g) . All animal studies were carried out in accordance with the regulations set out by the University of Western Ontario's Council on Animal Care, in agreement with the ARRIVE guidelines, and were carried out in accordance with the U.K. Animals Act, 1986 and associated guidelines.
Intravenous administration of the contrast agent and characterization of distribution in vivo
Five C57BL/6 male mice (25-30 g) were anesthetized initially with 4% isoflurane, and then 1.5% for maintenance, in O 2 via a nose cone placed on the snouts of the animals. The tail veins were catheterized using PE-20 polyethylene tubing. For each mouse, images were first acquired prior to contrast administration. The contrast agent (0.2 mL) was injected over a period of 3 minutes and three scans were acquired, starting 2 minutes following the end of injection and ending 60 minutes post injection. The 1:1 PEG 114 -PLA 53 :ErNP (mass ratio) was tested in 3 mice and the 0.5:1 mass ratio formulation was evaluated in 2 mice.
RESULTS AND DISCUSSION
Synthesis and characterization of oleate-coated ErNP
measurements of ErNP in THF reported a Z-average diameter of 50 ± 1 nm and a polydispersity index (PDI) of 0.18 ± 0.02 (Figure 2a and Figure S2) . These results were supported by TEM imaging (Figure 2b) . 
Synthesis and characterization of diblock copolymers
The ErNP are oleate-coated, which makes them incompatible with the aqueous blood pool. 33 It was envisioned that by nanoprecipitation of the ErNP with amphiphilic block copolymers, assemblies containing hydrophobic ErNP in the hydrophobic polymer cores and hydrophilic stabilizing polymer coronas would be formed ( Figure 1 ). Polymers are relatively easy to prepare, are colloidally stable even at low concentration, and can be synthesized at different lengths using various monomers, making them tunable and versatile materials. 34 We used PEG as the hydrophilic block for its well-known stealth properties against the immune system. 35, 36 In lieu of displacing the oleate on the ErNP surface with polymers, 29, 37 we chose to synthesize polymeric micelles by nanoprecipitation, which is a fast, reproducible, and cost-effective means of suspending hydrophobic cargo in polar solvents. 38 Displacing the oleate on the ErNP surface would favor the suspension of individual nanoparticles in solution, which is not a requirement in micro-CT.
To identify a carrier that would encapsulate high erbium content while surviving lyophilization and redispersion in saline, a series of amphiphilic block copolymers was studied ( Figure 3 , Table   1 ). Two PEG-PPG-PEG triblock copolymers (commonly referred to as poloxamers), which are commercially available, cost-effective and are FDA-approved for intravenous administration in humans, were used to form the polymeric assemblies. 39 In addition, several block lengths of PEG-PCL and PEG-PLA were synthesized and studied. These diblock copolymers were selected because they are used clinically as therapeutic drug carriers and are also currently in further clinical trials. 40 The characteristics of the polymeric micelles may change upon varying the copolymer's properties (i.e. hydrophobicity of the non-polar block, total block length, and PEG ratio). 41 Figure 3 . Chemical structures of the amphiphilic block copolymers that were used to form the polymeric assemblies. of the block ratios. The values indicated for the poloxamers were taken from their respective specification sheets. Overall, the measured M n values, particularly from NMR spectroscopy, and f values were in good agreement with the target structures.
Polymer self-assembly and ErNP encapsulation
First, the self-assembly of the block copolymers without ErNPs was investigated. The copolymers were dissolved in THF then this solution was added to water with stirring. After removal of THF by dialysis, the resulting nanoassemblies were characterized by DLS and TEM.
The Z-average diameters measured by DLS ranged from 11 to 55 nm (Table 2, Figure S15 ), consistent with self-assembly into micelles and TEM images confirmed that solid spherical particles were formed ( Figure S16 ). The PDIs ranged from 0.1 to 0.6, suggesting that some copolymers assembled into reasonably monodisperse nanoparticles (PDI < 0.3), whereas others exhibited a large distribution of sizes (PDI > 0.3). In general, the TEM results were in good agreement with the volume distributions obtained from DLS, except for both poloxamers (PEG 76 -PPG 22 -PEG 76 and PEG 137 -PPG 34 -PEG 137 ). For these poloxamers, the volume distribution in DLS suggested the presence of small scatterers that could be unassembled copolymers in solution,
whereas the corresponding TEM images showed larger nanoparticles that could result from aggregation during the drying process. Having confirmed the self-assembly behavior of the amphiphilic block copolymers alone, ErNPs were then added. Both the copolymer and ErNP were dissolved in THF and then nanoprecipitated into water to form suspensions of erbium-containing assemblies. The mass ratio of polymer:ErNP was 4:1. THF was removed by dialysis, then the suspensions were passed through a 0.45 µm filter.
This filtration served to remove any ErNP that had not been encapsulated and consequently aggregated, as well as polymer-ErNP assemblies that were too large and would be preferentially cleared from the blood by the mononuclear phagocytic system (MPS). 42, 43 The resulting assemblies were characterized by DLS and TEM (Figure 4 , Table 3 ). The TEM images showed individual displayed no specific organization or aggregation. This suggests the encapsulation of the ErNP within the amphiphilic block copolymers. It should be noted that the polymers were indiscernible in the TEM images because of the high contrast from the ErNP. The Z-average diameters that were measured by DLS ranged from 53 to 183 nm. This also supported the encapsulation of ErNP within the amphiphilic block copolymers, as these diameters were larger than those of the polymer-only micelles.
When PEG 114 -PLA 122 or any of the PEG-PCL diblock copolymers were used to form the assemblies, moderate PDIs (between 0.2 and 0.3) were observed. On the other hand, when using either poloxamers or the other PEG-PLA diblock copolymers good PDIs (< 0.2) were obtained.
Because the contrast agent was simply required to remain in circulation (i.e. no tissue-targeting was required), obtaining low PDIs was not of utmost importance; meeting the size requirements that would allow evasion of immediate renal clearance and preferential uptake by the MPS was sufficient. 
Redispersion and characterization of the lyophilized polymer-encapsulated ErNP
Because the polymer-encapsulated ErNP were prepared by nanoprecipitation at low concentrations in water, the sample had to be lyophilized then redispersed at higher concentrations.
The ability to lyophilize and resuspend the assemblies is also advantageous for their long-term storage. Dried samples were redispersed in 0.9% saline, which is isotonic with blood, and the Zaverage diameters of the assemblies were measured by DLS ( assemblies, which were initially 176 ± 6 nm, were redispersed in saline at 212 ± 2 nm ( Figure   S17 ). Given the very similar f values for these polymers, the larger PEG block is likely capable or better stabilizing the particles. All PEG-PCL assemblies redispersed in saline as micrometer-sized particles, which was undesirable, as these particles would be rapidly cleared by the MPS ( Figure   S18 ). The colloidal instabilities of PEG-PCL assemblies may result from PCL's high hydrophobicity or crystallinity. The PEG 45 -PLA 52 assemblies also redispersed as microparticles and PEG 114 -PLA 122 assemblies redispersed at an increased Z-average diameter of 301 ± 13 nm compared to an initial diameter of 130 ± 2 nm ( Figure S19 ). Both of these copolymers had low f values of ~0.3, which may contribute to their poor stability to redispersion. However, PEG 45 -PLA 25 and PEG 114 -PLA 53 assemblies retained Z-average diameters of 192 ± 4 and 134 ± 1 nm after redispersion in saline, similar to their initial diameters of 165 ± 2 and 154 ± 2 nm. Both remained colloidally stable for up to 60 minutes. This stability may result from their increased f values of ~0.5.
ICP-MS was used to quantify the concentration of erbium that was encapsulated by each system (Table 3 ). These measurements were performed on the initially prepared samples after their filtration. If all of the added erbium had remained dispersed in assemblies less than 0.45 µm in diameter, the expected erbium concentration of the suspensions would have been 780 µg/L. The highest erbium content was observed for PEG 114 -PCL 97 at 732 ± 22 µg/L. The second highest concentration was obtained with PEG 114 -PLA 53 at 599 ± 3 µg/L, then PEG 114 -PCL 51 at 596 ± 21 µg/L. However, out of the assemblies formed by these block copolymers, only PEG 114 -PLA 53 assemblies could be redispersed without a substantial increase in Z-average diameter in saline. The other block copolymers that allowed size consistency had lower erbium content, with PEG 137 -PPG 34 -PEG 137 at 232 ± 1 ug/L and PEG 45 -PLA 25 at 407 ± 2 µg/L. Decreased erbium content resulted from the filtration of unencapsulated hydrophobic ErNP that aggregated in water or ErNP in assemblies larger than 0.45 µm in diameter. Based on this analysis, further studies were performed with PEG 114 -PLA 53 as it was able to form stable assemblies with high erbium content.
Characterization of the assemblies formed with PEG 114 -PLA 53
The polymer content of the contrast agent does not contribute to the attenuation of x-rays and hence will not contribute to higher contrast. It does however contribute to the total mass of the material in solution, and increases viscosity, thereby making administration of the suspension difficult. Thus, it would be desirable to decrease the polymer:ErNP ratio in the assemblies.
However, decreasing the polymer content of the assemblies has one drawback, which is the potential decrease of their stealthiness and immune system evasion. 36 To investigate the possibility of lowering the polymer content of the contrast agent while retaining stability, assemblies were formed with lower PEG 114 -PLA 53 :ErNP mass ratios (from 4:1 to 2:1, 1:1 and 0.5:1). Their colloidal stabilities at 37 °C in saline and in a mouse serum mimic were studied by DLS ( Figure 5 ). The serum mimic contained bovine serum albumin and ions at concentrations that are similar to mouse blood. The proteins can potentially contribute to polymer shedding, and thereby to nanoparticle aggregation in vitro. In the blood pool of the animal in vivo, polymer shedding leads to the detection by the immune system and clearance of the nanoparticles from the blood via the liver. 35, 36 In the DLS analysis, the proteins generated insignificant scattering that did not interfere with the analysis of the assemblies (Figure S20-S21) . The Z-average diameters for the initially prepared assemblies ranged from 121-185 nm and did not vary significantly over a period of 60 minutes in saline or in the mouse blood mimic, indicating that each formulation was sufficiently stable. Using pyrene as a fluorescent probe, 44 the critical aggregation concentrations (CACs) for these 1:1 and 0.5:1 formulations were measured and compared to that of PEG 114 -PLA 53 assemblies without ErNP. We found that the CAC of the block copolymer alone was 26 mg/L, whereas those of the 1:1 and 0.5:1 PEG 114 -PLA 53 :ErNP formulations were 96 mg/L and 117 mg/L respectively ( Figures   S22-S24 ). Thus, it is evident that the loading of ErNP destabilizes the assemblies to some extent.
Nevertheless, these CAC values are much lower than the concentrations at which they would be administered, even after dilution into the blood pool. Figure S26 ). While higher erbium loading can be achieved with more concentrated solutions, we restricted the experiments to 100 mg/mL in order to maintain low viscosities for intravenous injection in mice.
Toxicity of the contrast agent
The in vitro and in vivo toxicity of the contrast agent was evaluated prior to its intravenous administration. Based on MTT assays, greater than 80% viability relative to controls was observed for the 1:1 polymer to erbium mass ratio formulation up to concentrations of 0.5 mg/mL ( Figure   S27 ). The 0.5:1 polymer to erbium formulation was even less toxic, with greater than 80% viability up to 1 mg/mL, the highest concentration tested. We also performed subcutaneous injections to study the materials in vivo. Subcutaneous tissue has slow absorption and clearance rates of exogenous materials, which provides an opportunity to study the reaction of tissues to the contrast agent over prolonged periods. Three-dimensional micro-CT images were obtained in mice before the subcutaneous injection of the 1:1 and 0. Figure S29 ).
Distribution of the contrast agent in vivo
Three-dimensional micro-CT images were obtained in mice before the intravenous In the 2 minute image in a), the external jugular veins (double arrowheads) and the axillary veins (arrows) are clearly visible.
Quantitative analysis indicated an increase in blood pool CT number of over 250 HU compared to pre-contrast values. The bladder was indistinguishable from pre-contrast values, indicating that the agent was not cleared through the renal system, as expected of materials that exceed the size of renal fenestrations. 14 By the one-hour mark, the liver and the spleen had increased up to 180 ± large nanoparticles are cleared through the MPS. 35, 36 In the myocardium, the CT number was just under 100 HU at all time points, which was expected of soft tissue in the absence of contrast material. As expected, the 0.5:1 polymer:ErNP assemblies demonstrated lower stealth activity, due to the lower amount of polymer used in the synthesis of the assembly, and were cleared from the blood more rapidly as indicated by the decreased intensity of the blood pool in the micro-CT images. Overall, this initial imaging study demonstrates that these new contrast agents can be dispersed and injected into mice at a concentration sufficient to achieve vascular contrast by micro-CT in vivo. Furthermore, the particles exhibited sufficient stealth properties to circulate in the vasculature for at least 1 hour. This suggests the promise of these new lanthanide-based agents for applications such as dual-energy imaging and spectral CT.
CONCLUSIONS
In this study, by systematically comparing a series of amphiphilic block copolymers composed of different hydrophobic blocks and different PEG mass fractions, we identified PEG 114 -PLA 53 as an amphiphilic copolymer that can encapsulate oleate-coated NaErF 4 nanoparticles. The PEG 114 -PLA 53 :ErNP assemblies redispersed into colloidally stable particles in saline after lyophilization and remained in the blood pool in vivo for at least an hour -a time period that well exceeds live animal micro-CT requirements. Importantly, we were able to formulate the assemblies at a high concentration of 100 mg/mL of erbium using PEG 114 -PLA 53 . At a delivered dose of 0.2 mL per mouse, this new contrast agent formulation resulted in the enhancement of blood pool in micro-CT images (at 80 kVp) by approximately 250 HU (above a soft tissue baseline of 100 HU) for at least an hour following contrast agent administration. This system should be readily adaptable for a variety of lanthanides, as the metal can be easily substituted in the oleate-coated NaErF 4 while retaining very similar properties, suggesting its promise as a new class of contrast agents for micro-CT as well as other imaging modalities such as MRI and optical imaging, in which lanthanides are utilized. Future studies will explore further the biodistribution and toxicity profiles of these agents.
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